

Huihui Ye

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6371126/huihui-ye-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49
papers

1,078
citations

17
h-index

32
g-index

55
ext. papers

1,422
ext. citations

6.6
avg, IF

3.87
L-index

#	Paper	IF	Citations
49	Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3705-15	2.2	169
48	Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. <i>Clinical Cancer Research</i> , 2015 , 21, 1273-80	12.9	129
47	SOX9 drives WNT pathway activation in prostate cancer. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1745-58	15.9	106
46	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. <i>Cancer Discovery</i> , 2017 , 7, 750-765	24.4	77
45	Clonal progression of prostate cancers from Gleason grade 3 to grade 4. <i>Cancer Research</i> , 2013 , 73, 1050-5	5.1	70
44	Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. <i>Clinical Cancer Research</i> , 2017 , 23, 6812-6822	12.9	58
43	Difficult differential diagnoses in testicular pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2012 , 136, 435-46	5	48
42	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. <i>Journal of Clinical Oncology</i> , 2019 , 37, 923-931	21.2	42
41	Rapid multi-orientation quantitative susceptibility mapping. <i>NeuroImage</i> , 2016 , 125, 1131-1141	7.9	38
40	EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021 , 2, 444-456	15.4	37
39	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. <i>Cancer Research</i> , 2018 , 78, 4716-4730	10.1	33
38	Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. <i>Clinical Cancer Research</i> , 2017 , 23, 3823-3833	12.9	30
37	ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3672-82	12.9	28
36	Downregulation of Accelerates Progression to Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018 , 78, 6354-6362	10.1	25
35	Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. <i>Human Pathology</i> , 2014 , 45, 2136-43	3.7	22
34	Comparing histologic evaluation of prostate tissue using nonlinear microscopy and paraffin H&E: a pilot study. <i>Modern Pathology</i> , 2019 , 32, 1158-1167	9.8	19
33	Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy. <i>Urology</i> , 2016 , 91, 143-9	1.6	17

32	Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	14
31	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , 2021 , 80, 746-757	10.2	14
30	BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. <i>Cancer Research</i> , 2018 , 78, 5203-5215	10.1	13
29	Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2020 , 80, 113-132	4.2	11
28	A case report of multiple primary prostate tumors with differential drug sensitivity. <i>Nature Communications</i> , 2020 , 11, 837	17.4	10
27	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020 , 78, 327-332	10.2	9
26	Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic 2018 , 6, 89		8
25	Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 560-568	6.2	7
24	MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity. <i>Oncogene</i> , 2020 , 39, 5663-5674	9.2	7
23	Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma. <i>Prostate</i> , 2016 , 76, 1227-36	4.2	7
22	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. <i>Clinical Cancer Research</i> , 2021 , 27, 4836-4847	12.9	6
21	Prostate cancer susceptibility gene is a modulator of androgen receptor signaling and epithelial to mesenchymal transition. <i>Oncotarget</i> , 2018 , 9, 28532-28546	3.3	5
20	Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. <i>Human Pathology</i> , 2019 , 94, 58-63	3.7	3
19	Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer		3
18	Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. <i>Human Pathology</i> , 2014 , 45, 2006-13	3.7	2
17	Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 79-79	2.2	2
16	Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer. <i>Molecular Oncology</i> , 2021 , 15, 1901-1920	7.9	2
15	Molecular correlates of intermediate- and high-risk localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 368-374	2.8	1

14	Author Reply. <i>Urology</i> , 2016 , 91, 148-9	1.6	1
13	Should the involvement of skeletal muscle by prostatic adenocarcinoma be reported on biopsies?. <i>Human Pathology</i> , 2016 , 49, 10-4	3.7	1
12	Neoadjuvant enzalutamide and androgen deprivation therapy for high-risk prostate cancer: Early results from a feasibility trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 94-94	2.2	1
11	Case of Basal Cell Carcinoma of the Prostate Successfully Treated Before and After a Reversion Mutation. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	1
10	Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2021.03.009 : Focus on Intraductal Carcinoma of the	10.2	1
9	CD70 is a promising CAR-T cell target in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 384-384	2.2	0
8	Donor-Derived Urothelial Carcinoma in Renal Transplant Recipients.. <i>Case Reports in Urology</i> , 2022 , 2022, 3353268	0.5	
7	Yolk sac differentiation in urothelial carcinoma - A rare variant originating from aberrant differentiation of sarcomatoid components.. <i>Annals of Diagnostic Pathology</i> , 2022 , 58, 151923	2.2	
6	Molecular and histopathologic correlates of imaging and biological responses to neoadjuvant GnRH agonist plus enzalutamide for high risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 34-34	2.2	
5	Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5082-5082	2.2	
4	A phase II study of nivolumab in patients with high-risk biochemically recurrent (BCR) prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS341-TPS341	2.2	
3	A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 63-63	2.2	
2	Molecular and imaging correlates of exceptional pathologic response to neoadjuvant ADT plus enzalutamide.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 61-61	2.2	
1	Genomic mechanisms of resistance to neoadjuvant leuprolide plus abiraterone in locally advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 98-98	2.2	